New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 11, 2014
11:51 EDTMYL, ACTMylan launches generic actonel tablets, 150 mg
Mylan (MYL) announced that it has launched Risedronate Sodium Tablets USP, 150 mg, the generic version of Warner Chilcott's (ACT) Actonel Tablets. Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for this product, which is indicated for the treatment and prevention of osteoporosis in postmenopausal women. Risedronate Sodium Tablets USP, 150 mg, had U.S. sales of approximately $171.6M for the 12 months ending March 31, according to IMS Health.
News For MYL;ACT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
May 28, 2015
09:17 EDTACTDrug approval great news for Actavis, says BMO Capital
BMO Capital says that FDA approval of Actavis' new drug for irritable bowel syndrome associated with diarrhea, Viberzi, is "great news" for the company. The firm thinks that Viberzi will be very complimentary to Linzess and future GI products, and it expects the launch to be successful. The firm keeps an Outperform rating on the shares.
08:24 EDTACTActavis added to Focus List with $360 target at Citigroup
Subscribe for More Information
06:11 EDTMYLTeva takes 1.35% stake in Mylan, says 'ready to meet' on deal
Subscribe for More Information
May 27, 2015
19:14 EDTACTOn The Fly: After Hours Movers
Subscribe for More Information
17:34 EDTACTActavis receives FDA approval for VIBERZI for treatment of IBS-D
Subscribe for More Information
12:10 EDTMYLTeva to sweeten offer for Mylan before July shareholder vote, NY Post says
Subscribe for More Information
May 25, 2015
13:56 EDTMYLMylan responds to claims of EPS forecasting by Perrigo
Mylan (MYL) announced that it was asked by the Irish Takeover Panel to issue the following clarification and retraction in accordance with the Irish takeover rules, relating to its firm intention to make an offer to acquire Perrigo (PRGO). The clarification and retraction relates to certain forward-looking statements made by Mylan specifically during the "pendency of the offer" period concerning its long-stated target since 2012 of at least $6.00 in adjusted EPS by 2018. Subsequent to Mylan's May 5 earnings release, Perrigo submitted a complaint to the Irish Takeover Panel alleging that the reference to Mylan's $6.00 long-term target should be treated as a forward-looking profit forecast statement. Although Mylan's adjusted EPS goal has been a stated long-term target, and not a forecast of Mylan, at least during the offer period as it pertains to the Perrigo transaction, Mylan will no longer refer to that 2018 target or any other forward looking statements beyond 2015 that could constitute profit forecasts.
May 22, 2015
16:07 EDTACTActavis confirms court ruling requiring continued distribution of NAMENDA IR
Actavis confirmed that a panel of the U.S. Court of Appeals for the Second Circuit has issued a ruling upholding a December 15, 2014 preliminary injunction requiring the company to continue distribution of NAMENDA immediate-release tablets. Actavis noted that the company will continue to manage sales and R&D expenses to ensure that the Appeals court's decision will have minimal to no impact on its 2015 NAMENDA franchise contribution to earnings and longer term company earnings aspirations.
13:19 EDTACTNY AG says ruling on Actavis Alzheimer’s drug a victory for patients
New York Attorney General Eric Schneiderman, following a decision by the U.S. Court of Appeals for the Second Circuit to affirm the federal district court decision granting New York’s motion for a preliminary injunction against defendants Actavis and Forest Laboratories, stated: "Today’s appeals court decision is a sweeping victory for consumers and Alzheimer’s patients. Our lawsuit and the court’s injunction protect competition and prevent Actavis from coercing Alzheimer’s patients into taking drugs they do not want in order to charge them monopoly prices...My office will continue to protect New Yorkers from anticompetitive practices by drug manufacturers.”
11:26 EDTACTCourt rules Actavis can't pull Alzheimer's drug for pricer new one, Reuters says
A three-judge panel of a New York appeals court upheld a prior order requiring Actavis to keep the older version of its Alzheimer's drug, Namenda IR, on the market following the company's launch of a more expensive extended-release version, reported Reuters. Reference Link
11:23 EDTACTCourt rules Actavis can't pull Alzheimer's drug for pricer new one, Reuters says
Subscribe for More Information
10:52 EDTACTJPMorgan says Actavis shares cheap compared to peers
Subscribe for More Information
07:44 EDTACTActavis trades at over 20% discount to Major Pharma, says JPMorgan
Subscribe for More Information
May 19, 2015
06:08 EDTMYLPerrigo CEO says would talk with Mylan, but at a higher price, Globes reports
Subscribe for More Information
May 18, 2015
12:07 EDTMYLPerrigo: there is price point where would engage with Mylan, Bloomberg reports
Subscribe for More Information
11:21 EDTACTAckman sold out of Actavis stake after Q1 report, NY Post says
Subscribe for More Information
08:01 EDTACTActavis launches Namzaric to treat moderate to severe Alzheimer's
Actavis announced that NAMZARIC, a once-daily, fixed-dose combination of memantine hydrochloride extended-release, and donepezil hydrochloride, is now available to patients and healthcare professionals across the United States. NAMZARIC was approved by the FDA in December for the treatment of moderate to severe Alzheimer's disease in patients stabilized on memantine hydrochloride and donepezil hydrochloride.
07:22 EDTMYL, ACTUBS to hold a conference
Global Healthcare Conference is being held in New York on May 18-20 with webcasted company presentations to begin on May 18 at 8 am; not all company presentations may be webcasted. Webcast Link
07:15 EDTACTPhysician feedback on Actavis Eluxadoline positive, says RBC Capital
After conducting a survey, RBC Capital says that physician enthusiasm about Actavis' Eluxadoline is high ahead of its expected early 2016 launch. The firm thinks the drug could be an important P&L driver for the company and keeps a Top Pick rating on the shares.
06:58 EDTACTActavis CEO says chances of Pfizer offer are 'unlikely', Financial Times says
Actavis (ACT) CEO Brent Saunders said the chances of Pfizer (PFE) making an offer are "incredibly unlikely," reports the Financial Times. Saunders said he has heard the gossip that Actavis could become a takeover target for a larger group, but he spends "zero time thinking about it." Reference Link
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use